Biosig Technologies Inc

BioSig Technologies, Inc. is a medical technology company, which engages in the development of a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of electrocardiographic and intra-cardiac signals. Its product PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording, and storing of electrocardiographic and intra-cardiac signals for patients undergoing electrophysiology procedures. The company was founded by Kenneth L. Londoner on February 24, 2009 and is headquartered in Westport. CT.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioSig Technologies Inc (NASDAQ: BSGM), a medical device company, announced Friday a commercial milestone with respect to its FDA-approved PURE EP Systems. What Happened: Westport, Connecticut-based BioSig said it sold three PURE EP Systems to St. David's HealthCare of Austin, Texas.

BioSig Announces First Sale Of Cardiac Signal Processing Systems

Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence Sale Marks Milestone for Company's Commercial expansion at leading Center of Excellence

BioSig Achieves First Commercial Sale of Three PURE EP Systems

Westport, CT, Dec. 10, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc. will be presenting live to a virtual audience at the 13th Annual LD Micro Main Event Conference on Monday, December 14, 2020 at 10:20 AM ET.

BioSig CEO Kenneth L. Londoner to Present at the 13th Annual LD Micro Main Event Conference

Company's flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020 Company's flagship product to be featured in live patient cases broadcast from the Texas Cardiac Arrhythmia Institute on December 3-4, 2020

BioSig's PURE EP System to Support Live Patient Cases during EPLive 2020

BioSig Technologies, Inc. (BSGM) CEO Ken Londoner on Business Development Update Conference Call (Transcript)

Westport, CT, Nov. 12, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it would host a call on November 18, 2020, at 4:15 PM ET. Kenneth L. Londoner, Chairman, and CEO of BioSig Technologies, Inc. will review highlights from the Company's third quarter of 2020 and discuss corporate initiatives, including ongoing PURE EP™ System installations and commercialization outlook.

BioSig to Host Business Update Conference Call on November 18, 2020

First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center First Patient Cases with PURE EP System Conducted at Deborah Heart and Lung Center

BioSig Announces Completion of PURE EP™ System Installation at New Medical Center

Westport, CT, Oct. 28, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company had issued an October 2020 Letter to Shareholders providing highlights on the Company's recent developments and updates.

BioSig Issues October 2020 Shareholder Update Letter

BioSig Technologies Inc. (NASDAQ: BSGM) was absolutely crushed on Monday after the company announced that it would halt its midstage coronavirus study.

The Big COVID-19 Update at BioSig Technologies

Shares of Biosig Technologies Inc. plunged 39.0% in active morning trading Monday, enough to pace all Nasdaq decliners, after the medical technology company halted a trial of its COVID-19 treatment given disappointing results. Trading volume was 2.0 million shares, already nearly triple the full-day average of about 693,000 shares.

Biosig stock plunges to lead Nasdaq losers after trial of COVID-19 treatment halted

Westport, CT, Oct. 26, 2020 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), announced the halting of its signal finding Phase 2 trial, “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Oral Merimepodib in Combination with Intravenous Remdesivir in Adult Patients with Advanced Coronavirus Disease 2019 (COVID-19)”.

ViralClear halts its Phase 2 Hospitalized COVID-19 Trial

Westport, CT, Sept. 30, 2020 (GLOBE NEWSWIRE) -- ViralClear Pharmaceuticals, Inc. (Nasdaq BSGM) and Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced the companies are exploring the synergistic potential of small molecules and antibodies combination therapies against COVID-19.

SORRENTO THERAPEUTICS AND VIRALCLEAR ENTER INTO AGREEMENT TO EXPLORE THE COMBINATION OF ANTIBODY AND ANTIVIRAL ASSETS AGAINST COVID-19

Westport, CT, Sept.  22, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”) and its majority owned subsidiary, ViralClear Pharmaceuticals, Inc.  (ViralClear), today conducted an investor update call on Viral Clear’s merimepodib drug development program for the treatment of COVID-19.

ViralClear Expands Ongoing Phase 2 Trial Size for its Oral Anti-Viral for the Treatment of COVID-19, Expands Trial Locations and Appoints Contract Manufacturing Organization to Manufacture Phase 3 Supplies of Merimepodib Oral Solution

Westport, CT, Sept.  21, 2020  (GLOBE NEWSWIRE) --    BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that it will host a call and webcast to discuss its Phase 2 clinical trial.  The study is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of merimepodib (MMPD) in combination with remdesivir for hospitalized adult patients who have confirmed infection with SARS-CoV-2 and require non-invasive ventilation/high flow oxygen devices or supplemental oxygen (score of 3 or 4, respectively, on the NIAID 8-point ordinal scale).  The trial is being conducted at 10 investigational sites across the United States (US), with Dr. Andrew Badley, the chair of Mayo Clinic COVID-19 Research Task Force serving as the study director.    

Reminder: ViralClear to Host Conference Call and Webcast on September 22, 2020 to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis.  Abstract concludes PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems. Positive responses confirm that the PURE EP signals are preferred to conventional sources of intracardiac signals in a blinded, independent analysis.  Abstract concludes PURE EP™ System is able to produce reliable and high-quality signals when compared to the available standard of care systems.

BioSig Releases PURE EP Study Abstract with Data Presented at European Society of Cardiology’s ‘ESC Congress 2020’

Westport, CT, Sept.  14, 2020  (GLOBE NEWSWIRE) --  BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company’s abstract for ‘Computational Reconstruction of Electrocardiogram Lead Placement’ was accepted for presentation at the 2020 Computing in Cardiology Conference (CinC).

BioSig Announces Abstract Acceptance to Computing in Cardiology 2020

Westport, CT, Sept.  14, 2020  (GLOBE NEWSWIRE) --  Westport, CT, September 14, 2020 — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it will host a call and webcast to discuss the results from the first randomized, blinded signal sample analysis in the PURE EP 2.0 Clinical Study. The data was generated during atrial fibrillation ablation procedures conducted at St. David’s Medical Center, Austin, Texas.  

Reminder: BioSig to Host Conference Call and Webcast on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

Westport, CT, Sept.  09, 2020  (GLOBE NEWSWIRE) --    BioSig Technologies, Inc. ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced that it will host a conference call to discuss its Phase 2 clinical trial.  The study is a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of merimepodib (MMPD) in combination with remdesivir for hospitalized adult patients who have confirmed infection with SARS-CoV-2 and require non-invasive ventilation/high flow oxygen devices or supplemental oxygen (score of 3 or 4, respectively, on the NIAID 8-point ordinal scale).  The trial is being conducted at 5 investigational sites across the United States (US), with Dr. Andrew Badley, the chair of Mayo Clinic COVID-19 Research Task Force serving as the study director.    

ViralClear to Host Conference Call on September 22, 2020, to Discuss Phase 2 Human Trial of AntiViral Merimepodib Oral Solution for Treatment of COVID-19

Westport, CT, Sept.  02, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced it will host a call to discuss the results from the first randomized, blinded signal sample analysis in the PURE EP 2.0 Clinical Study. The data was generated during atrial fibrillation ablation procedures conducted at St. David’s Medical Center, Austin, Texas.  

BioSig to Host Conference Call on September 15, 2020 to Discuss Unblinding of PURE EP Human Data

Westport, CT, Aug.  25, 2020  (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it will be presenting at the 12th Annual LD 500 Conference on Wednesday, September 2, 2020, at 11:40 AM ET.  Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, will present virtually to an online audience.  

BioSig Technologies to Present at The LD 500 Virtual Conference

BioSig is two investment opportunities rolled into one. An early-stage electrophysiology play, and a late-stage COVID-19 vaccine candidate.

BioSig Technologies: Surprise COVID-19 Vaccine Offers 2 Upside Opportunities For The Price Of 1

Westport, CT, Aug.  06, 2020  (GLOBE NEWSWIRE) --

Infectious Diseases Expert Prof. Angus Dalgleish Joins ViralClear’s Scientific Advisory Board

Westport, CT, Aug.  05, 2020  (GLOBE NEWSWIRE) --    BioSig Technologies, Inc.  ’s (Nasdaq: BSGM) (“BioSig” or the “Company”) subsidiary, ViralClear Pharmaceuticals, Inc. (ViralClear), today announced the addition of Dr. Michael J. Sofia to its Scientific Advisory Board (SAB).

ViralClear Appoints Dr. Michael Sofia to Its Scientific Advisory Board

Patient cases are set to commence in August Patient cases are set to commence in August

BioSig Installs PURE EP(tm) System at Massachusetts General Hospital

Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. government Company moves forward with the qualification to bid for contacts, grants and to do business with the U.S. government

News for Biosig Technologies Inc Stock (BSGM)